Navigation Links
Sutro Biopharma Forges Partnership with Pfizer for Discovery, Development and Commercialization of Novel Peptide-Based Therapeutics
Date:1/7/2011

ro's biochemical protein synthesis technology opens up opportunities to create protein therapeutics that cannot be produced using conventional methods. Sutro's technology enables the rapid and systematic exploration of many protein drug variants to identify drug candidates. Once identified, the company can efficiently scale production to commercial levels. In addition to developing its own drug pipeline, Sutro is collaborating with select pharmaceutical and biotechnology companies in the development of novel protein therapeutics that cannot be designed, produced or studied with current technologies.Media Contacts:David Schull or Martina Schwarzkopf, Ph.D.Russo Partners(212) 845-4271 (212) 845-4292 (347) 591-8785 (mobile)david.schull@russopartnersllc.commartina.schwarzkopf@russopartnersllc.com
'/>"/>
SOURCE Sutro Biopharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
3. Ondine Biopharma Announces Second Quarter 2008 Financial Results
4. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
5. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
6. Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools
7. Therapure Biopharma Inc. opens for business with first client contracts
8. Top Biopharma Company Adopts BioFortis Translational Research Software for Centralized Management and Mining of Clinical Biomarker Data
9. China Biopharma Effects 1 for 100 Reverse Stock Split
10. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
11. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 26, 2015 S&P Capital IQ (MHFI) announced ... coverage on MabVax Therapeutics Holdings Inc . ... stage biotechnology company focused on the development of vaccine ... the treatment of cancer. MabVax has discovered a pipeline ... immune responses generated by patients who have been immunized ...
(Date:2/26/2015)... 26, 2015  23andMe, the leading personal genetics company, ... as Privacy Officer and Corporate Counsel. Black brings a ... as well as health care regulations. As a member ... responsible for reviewing, updating and enhancing the company,s privacy ... abroad. She joined the company January 5, 2015 and ...
(Date:2/26/2015)... Synageva BioPharma Corp. (NASDAQ: GEVA ... rare disorders, today reported 2014 full year financial ... and financial guidance.  Synageva,s management team will host ... to review the financial results and provide a ... by telephone, please dial (877) 445-4603 for U.S. ...
(Date:2/26/2015)... PARK, Calif. , Feb. 26, 2015 ... released the latest version of the Governance Portal ... accomplish governance, risk and compliance (GRC) tasks across multiple ... also been updated to help customers better align their ... of the Treadway Commission ) requirements. In response to ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 523andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3
... Bio Inc. (ORC) a biotech company developing stem ... with the European Competent Authority in Seville, Spain, ... HYC750 in healthy male volunteers. The goal of ... pharmacokinetics and pharmacodynamics (induction of hematopoiesis) of HYC750, ...
... SHENYANG, China, Feb. 9 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc.,(Nasdaq: ... focused on researching,developing, manufacturing and marketing biopharmaceutical products ... Mr. Bo Tan as Chief Financial,Officer, effective February ... Mr.,Tan has been acting as the financial advisor ...
... DUBLIN, Ireland, February 9, Shire plc (LSE: SHP, NASDAQ: ... IV Notice letters from Barr Laboratories, Inc.,("Barr) and Mylan, ... in each case of the filing of an Abbreviated ... 750mg and 1gm FOSRENOL(R),(lanthanum carbonate). , ...
Cached Biology Technology:Orcrist Bio Inc. Files with European Competent Authority for a Phase I, Open-label, Single-ascending-dose, Safety Study of HYC750 2Orcrist Bio Inc. Files with European Competent Authority for a Phase I, Open-label, Single-ascending-dose, Safety Study of HYC750 33SBio Inc. Appoints Mr. Bo Tan as Chief Financial Officer 2Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan 2
(Date:2/23/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announced today ... DISTRIBUTED VOICE DIRECTED PAYMENT METHOD AND SYSTEM. ... payment method. Payment accounts may be selected via voice ... if both the speech (the word associated with the ...
(Date:2/12/2015)... Minn. , Feb. 12, 2015   ... company specializing in clinical study management systems, has ... Program , further distinguishing iMedNet ... Clinical Research Organizations (CROs) and healthcare consultants.  Building ... support, prospective customer referrals and numerous co-marketing opportunities), ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America ... methods for carbon nanotube (CNT) macrostructures, including sheets, yarns ... Dallas (UTD). Leveraging the vast industrial resources ... Tokyo, Japan , Lintec of America is forming ... Richardson, TX , focusing on scaling up the ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... and doctors from universities and industries around the ... project announced Sept. 4 to develop implantable devices ... designed to adapt to physical changes in a ... Naturally dissolving plates, screws, stents, and other devices ...
... 2008 As the anniversary of the September 11 ... a new podcast describing an array of technologies to ... podcast is the sixth episode in ACS,s acclaimed ... twice monthly, Global Challenges examines daunting problems facing society ...
... a gene enhancer, known as HACNS1, that may have contributed ... possibly also modifications in the ankle or foot that allow ... published in Science on Sept. 5, 2008. ... existence of human-specific gene enhancers, which are switches near genes ...
Cached Biology News:Project aims to reduce complications, multiple surgeries with biodegradable implantable devices 2Project aims to reduce complications, multiple surgeries with biodegradable implantable devices 3Project aims to reduce complications, multiple surgeries with biodegradable implantable devices 4New 'chemical radar' among national security innovations in ACS podcast 2New 'chemical radar' among national security innovations in ACS podcast 3Gene enhancer in evolution of human opposable thumb 2Gene enhancer in evolution of human opposable thumb 3
Chicken polyclonal antibody to Glutathione-S-Transfrease (GST)...
... BODIPY FL ATP-Gamma-S binds to ... nucleotide the BODIPY FL fluorophore was ... In addition to its potential use ... ATP-Gamma-S thioether is an important new ...
... the industry standard microarray image analysis software ... and analysis tools, visualizations, automation capabilities, performance ... included with every GenePix scanner, and it ... and all types of arrays. A wide ...
... Simplify the process and you reduce the ... into the CEQ 8000. Developed using Beckman ... leadership in capillary electrophoresis technology, the CEQ ... system. This system automatically fills the capillary ...
Biology Products: